Bayer loses out as India issues its first compulsory licence
The Indian Patent Office has today decreed that Bayer must license the right to produce its patented anti-cancer treatment Nexavar to generic company Natco. This is the first compulsory licence issued in India since the country signed up to TRIPs…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.